U.S. Insulin Drug Market

Medicare began paying a negotiated USD 119 for a 30-day supply of Novo Nordisk’s NovoLog and Fiasp on 1 January 2026, 76% below list, PBS NewsHour reported when the Centers for Medicare & Medicaid Services (CMS) published the prices; from the same day California’s CalRx glargine pens were priced at USD 55 for five, according to CalRx. American insulin is now sold on price, not on brand. The U.S. insulin drug market covers human and analogue insulins, including once-weekly basal insulin, sold for use in the United States, valued at manufacturer net prices after rebates. Douglas Insights sizes it at USD 6.10 billion in 2025, from 7.20 million insulin patient-years at an average net USD 847 each, and at USD 6.87 billion in 2035, a revenue CAGR (compound annual growth rate) of 1.19%. It is the U.S. cut of our global Insulin Drug Market report, sits in our pharmaceuticals coverage, and every figure follows the Douglas Insights research methodology.

Which U.S. insulin class earns most now that NovoLog has a Medicare price: basal, mealtime, human or premix?

Long-acting basal insulin earns most, 48.0% of 2025 U.S. insulin value, USD 2.93 billion, and grows fastest, 2.50% a year to USD 3.75 billion, because once-weekly basal insulin launches at a premium.

Long-acting analogues, USD 2.93 billion, lead because basal insulin is the first injectable step for most people with type 2 diabetes. Sanofi’s Lantus and Toujeo, Novo Nordisk’s Tresiba, Lilly’s Basaglar and the Semglee and Rezvoglar copies all compete here, and two once-weekly products arrive in 2026. The class grows 2.50% a year because weekly basal insulin cuts 365 injections to 52 and carries a higher price per patient than daily glargine.

Rapid-acting analogues, USD 2.20 billion, are mealtime and pump insulins such as Humalog, NovoLog, Fiasp, Admelog and Lyumjev. They grow only 0.10% a year because the Medicare negotiated price on NovoLog and Fiasp and interchangeable aspart copies pull net prices down while pump users add volume; pumps themselves are sized in our Insulin Pumps Market report. Human insulin, USD 549 million, grows 0.50% a year on low-cost vials sold over the counter and concentrated U-500 for insulin-resistant patients. Premix insulins, USD 427 million, shrink 2.00% a year as prescribers move patients to basal-plus regimens. Class values for 2035 sum to USD 6.89 billion, 0.34% above the headline.

By delivery format, Douglas Insights estimates that prefilled pens carry about 64% of 2025 value, vials about 30% and cartridges for pumps and reusable pens about 6%. The pen share rises every year because the CalRx glargine launch, the weekly products and most new copies come as pens first. By channel, retail pharmacies dispense about 72% of value, mail-order pharmacies about 18% and hospitals and clinics about 10%, Douglas Insights estimates; mail order gains share because pharmacy benefit managers steer 90-day insulin refills to their own pharmacies.

Why does the number of Americans on insulin keep rising 1.60% a year despite GLP-1 drugs?

More diagnosed diabetes keeps U.S. insulin volume rising 1.60% a year, from 7.20 million patient-years in 2025 to 8.44 million in 2035. Four drivers add 2.20 points; GLP-1 drugs take back 0.50.

The Centers for Disease Control and Prevention (CDC) counts 40.1 million Americans with diabetes in 2023, 12.0% of the population, of whom 29.1 million are diagnosed and about 11.0 million undiagnosed, with 2.1 million living with type 1 diabetes, in its National Diabetes Statistics Report, updated on 16 September 2026. Every person with type 1 diabetes needs insulin for life, and type 2 patients add it as the disease progresses.

More diagnosed type 2 diabetes: 1.20 points

Prevalence adds 1.20 points. An ageing and heavier population raises the diagnosed count, and about a quarter of diagnosed patients reach insulin, Douglas Insights estimates; finding some of the 11.0 million undiagnosed adds more.

Once-weekly basal starts: 0.40 points

Weekly insulin adds 0.40 points. Novo Nordisk announced U.S. approval of Awiqli on 27 March 2026, according to its filing with the SEC, and the Food and Drug Administration (FDA) approved Lilly’s Onswik (insulin efsitora alfa-gobe) for adults with type 2 diabetes on 24 September 2026 after the four QWINT trials in more than 3,400 adults, Pharmacy Times reported. Fewer injections help doctors start patients who refuse daily shots.

Affordability caps: 0.30 points

Caps add 0.30 points. Medicare Part D has limited insulin out-of-pocket costs to USD 35 a month since 1 January 2023, and from 2026 a Medicare member pays the lowest of USD 35, 25% of the negotiated price or 25% of the plan price, Prime Therapeutics explains. Fewer patients ration doses when the copay is capped.

Type 1 technology: 0.30 points

Pumps and continuous glucose monitors add 0.30 points, as automated systems raise the share of type 1 patients on rapid-acting insulin and keep them in care. The four drivers total 1.20 + 0.40 + 0.30 + 0.30 = 2.20 points.

What holds back U.S. insulin value: GLP-1 drugs, negotiated prices or USD 55 copies?

Net price is the main brake: the U.S. insulin price per patient-year falls 0.40% a year, from USD 847 to USD 814 by 2035. On volume, GLP-1 drugs remove 0.50 points and gaps in diagnosis 0.10 points.

GLP-1 and GIP drugs such as semaglutide and tirzepatide delay the point at which a type 2 patient needs insulin, so each year fewer patients start basal therapy than diabetes prevalence alone would imply. Douglas Insights removes 0.50 points. Slow diagnosis removes 0.10 points, because the 11.0 million undiagnosed Americans cannot be treated.

The price leg loses 1.30 points and gains 0.90. The NovoLog and Fiasp negotiated price takes 0.50 points as it pulls commercial rebates down with it; interchangeable biosimilars and unbranded copies take 0.50 points; and the CalRx glargine pen at USD 55 for five takes 0.30 points as other buyers use it as a benchmark. The weekly basal premium adds 0.60 points and the shift from vials to pens 0.30 points, leaving -0.40%.

The result is a market that adds patients faster than dollars. Novo Nordisk said its U.S. insulin sales benefited from gross-to-net adjustments and a favourable channel and payer mix that offset lower volumes, while its U.S. volume share fell from 32.5% to 28.9% in 2025, according to its 2025 financial report.

Where in the United States is insulin used most, and why does the South grow fastest?

The South uses most U.S. insulin, USD 2.50 billion or 41.0% of 2025 value, and grows fastest, 1.55% a year to USD 2.92 billion by 2035, because it combines high diabetes prevalence with the fastest population growth.

The South, USD 2.50 billion, includes Mississippi, Alabama, Louisiana and West Virginia, among the states with the most diagnosed diabetes per resident, and Texas and Florida add the most residents, so insulin starts grow there first. The West, USD 1.22 billion, grows 1.30% a year; California is the exception on price, because the CalRx pen at USD 55 for five sets a lower benchmark for state buyers.

The Midwest, USD 1.28 billion, and the Northeast, USD 1.10 billion, grow 0.80% and 0.65% a year as their populations age without growing, and both have state copay caps that already widened access before 2025. Regional values for 2035 sum to USD 6.86 billion, 0.07% below the headline; in the data table the row labelled Global holds the U.S. total, USD 6.10 billion in 2025.

Who sells U.S. insulin: Lilly, Novo Nordisk, Sanofi or the biosimilar makers?

Novo Nordisk sells the most U.S. insulin by value, USD 2.31 billion or 37.8% of 2025 net value, from its filed sales. Lilly holds about 35.0% and Sanofi 21.3%, so three originators hold 94.1%.

Novo Nordisk’s U.S. insulin sales were DKK 15,234 million in 2025, down 2% in kroner but up 2% at constant exchange rates, which we convert at DKK 6.60 per dollar from 2025 European Central Bank reference rates. Sanofi’s U.S. Lantus sales rose 32.1% at constant exchange rates to EUR 808 million, Toujeo 15.2% to EUR 240 million and Soliqua 40.0% to EUR 100 million, according to Sanofi’s 29 January 2026 results; Sanofi gained the volume Novo lost.

Lilly does not disclose U.S. insulin sales in its results release, so its 35.0% is a Douglas Insights estimate. Lilly cut Humalog and Humulin list prices by 70% in 2023 and capped patient costs at USD 35, according to Eli Lilly, and now adds Onswik. Biocon Biologics won FDA approval of Kirsty, the first interchangeable rapid-acting insulin aspart, in 2025, according to Biocon. The wider ranking of these companies across all medicines sits in our U.S. Pharmaceutical Drug Market report.

What does a month of insulin cost a U.S. buyer, from USD 35 copays to the USD 119 Medicare price?

A U.S. insulin patient-year earned manufacturers an average net USD 847 in 2025, about USD 70.6 a month, Douglas Insights estimates, far below list prices. Published prices now range from USD 35 copays to USD 119.

At a typical basal dose of 40 units a day, the CalRx pack lasts about 37 days, or about USD 44 a month, below our USD 70.6 average net price per patient-month. That gap explains the price leg: each time a payer switches a patient from a rebated brand to a low-list copy, the manufacturer’s net price per patient falls even if the patient’s copay does not change. Douglas Insights projects USD 844 per patient-year in 2026 and USD 814 in 2035.

Weekly basal insulin is the counterweight. It enters at brand prices with no copy, and its share of basal starts rises through the decade. The U.S. average net price per patient-year stays above the USD 521 global average in our model because U.S. patients use more analogues and pens.

How do Medicare negotiation, interchangeability and state programmes change U.S. insulin pricing?

Three rules change U.S. insulin pricing: Medicare negotiated prices from 1 January 2026, FDA interchangeable status for biosimilar insulins, and state programmes such as CalRx with its USD 55 glargine pens.

Under the Inflation Reduction Act, CMS negotiated a price for NovoLog and Fiasp among the first ten drugs, effective 1 January 2026; across all ten drugs it estimated that the negotiated prices would have cut 2023 net Medicare spending by about USD 6 billion, or 22%, in its negotiated prices fact sheet. The same law has capped Medicare insulin copays at USD 35 since 2023. More insulins can be selected in later rounds, which caps the upside on any brand that Medicare spends heavily on.

The FDA’s interchangeable designation lets pharmacists substitute a biosimilar insulin without a new prescription, and Civica’s CalRx glargine is interchangeable with Lantus, according to CalRx. California also lets the pens be priced to include distribution and pharmacy dispensing, so the USD 55 is a shelf price, not a list price.

Product approvals complete the rule set: Awiqli on 27 March 2026 and Onswik on 24 September 2026 make the United States the first market with two once-weekly basal insulins, and both must win formulary places from pharmacy benefit managers that already hold rebates on daily basal brands.

What if weekly insulin takes off or GLP-1 drugs delay insulin longer: where does U.S. insulin land in 2035?

The U.S. insulin drug market ends 2035 between USD 5.85 billion and USD 8.05 billion across our three cases, around a base of USD 6.87 billion. Weekly basal uptake and GLP-1 substitution set the spread.

In the slower case GLP-1 and GIP drugs keep most type 2 patients off insulin for years, Medicare selects more insulins for negotiation and weekly basal insulin stays a niche. In the faster case weekly products win broad formulary cover and doctors start insulin earlier in type 2 diabetes. One extra point of yearly volume growth adds USD 707 million to 2035 value; one point less removes USD 647 million.

Our 1.19% base sits below the 1.62% North America rate in our global insulin model and well below the 2.46% global rate, because U.S. net prices fall while prices elsewhere are already low.

Douglas Exclusive: the U.S. Insulin Net Price Ladder

The U.S. Insulin Net Price Ladder is a Douglas Insights model built from 10 sourced inputs, 3 company filings, 2 FDA approvals, 3 government programmes and 2 statistics releases, ranking every published U.S. insulin price against our average net price.

The finding, a Douglas Insights estimate: a low-cost copy now sits 38% below the average net revenue manufacturers earn per patient-month, so every patient moved to it removes about USD 26.6 a month, about USD 319 a year, from branded net sales. Novo Nordisk lost 3.6 points of U.S. volume share in 2025 while Sanofi’s U.S. Lantus grew 32.1%, which shows how fast patients move between basal brands once payers change the formulary. Weekly basal insulin, which no copy can match before the 2030s, is where originators will defend value.

How does the methodology turn 7.20 million patient-years into USD 6.10 billion of U.S. insulin?

Our methodology multiplies 7.20 million U.S. insulin patient-years in 2025 by an average net USD 847 per patient-year to reach USD 6.10 billion. Patients come from CDC counts; price from company filings.

The model covers 4 Census regions, 4 insulin classes, 2 diabetes types, 3 delivery formats and 3 channels, and uses 52 data points, 12 sourced and 40 modelled. Arithmetic: 7.20 million x USD 847 = USD 6,098.4 million; 6,098.4 x (1.0160 x 0.9960)^10 = USD 6,866.7 million, or USD 6.87 billion. Patient-years reach 7.32 million in 2026 and 8.44 million in 2035. About 2.1 million of the 7.20 million are type 1 patients, matching the CDC count.

Two cross-checks agree. First, Novo Nordisk’s USD 2.31 billion and Sanofi’s USD 1.30 billion of filed U.S. insulin sales sum to 59.1% of our total, which leaves a plausible USD 2.49 billion for Lilly and the copy makers. Second, our net-price total is 66.3% of the USD 9.19 billion North America value in our global insulin model, which is built on a broader price basis; the global figure will be aligned at its next review. AI tools help draft the text and automated checks test the arithmetic and links; the Douglas Insights research desk chooses the sources, builds the model and approves publication, as our editorial standards explain.

Sources

1. Centers for Disease Control and Prevention National Diabetes Statistics Report (2026)
2. Centers for Medicare and Medicaid Services Medicare Drug Price Negotiation Program: negotiated prices for initial price applicability year 2026 (2024)
3. PBS NewsHour Here's a list of drugs affected by Medicare price cuts (2024)
4. State of California, CalRx CalRx biosimilar insulin initiative (2026)
5. Novo Nordisk / SEC Financial report for 2025 (Form 6-K) (2026)
6. Novo Nordisk / SEC US approval of once-weekly Awiqli (Form 6-K) (2026)
7. Sanofi / SEC Q4 and full-year 2025 results (Form 6-K) (2026)
8. Pharmacy Times FDA approves insulin efsitora, once-weekly basal insulin, for adults with T2D (2026)
9. Eli Lilly Lilly cuts insulin prices by 70% and caps patient insulin out-of-pocket costs at USD 35 (2023)
10. Biocon Biologics FDA approval of Kirsty, interchangeable insulin aspart (2025)
11. Prime Therapeutics Overview of maximum fair price for insulin under Medicare Part D (2026)

Which insulins does this U.S. study count, and what does it leave out?

The U.S. insulin drug market counts manufacturer net sales of human and analogue insulins, weekly basal insulins and inhaled insulin used in the United States. Glucagon, GLP-1 drugs, pumps, pens sold empty and pharmacy margins stay out.

The by-class split covers long-acting analogues, rapid-acting analogues, human insulin and premix insulins; basal insulin and GLP-1 fixed-ratio combinations such as Soliqua count in long-acting. The by-channel split covers retail, mail-order and hospital pharmacies. The by-region split covers the South, Midwest, West and Northeast. Values are net of rebates to pharmacy benefit managers, Medicaid and the 340B programme. Insulin bought for export and insulin used in clinical trials are excluded. The German market, where insulin sits inside a much larger biologics bill, is sized in our Germany Pharmaceutical Drug Market report.